
Bioorganic and Medicinal Chemistry Letters p. 1574 - 1580 (2018)
Update date:2022-09-26
Topics:
Rai, Reeta
Dutta, Roshan Kumar
Singh, Surjeet
Yadav, Dharmendra Kumar
Kumari, Seema
Singh, Harpreet
Gupta, Rinkoo Devi
Pratap, Ramendra
A series of functionalized naphthalene was synthesized and screened against human prostate cancer cell line (PC-3). The in vitro antiproliferative activity of the synthesized compounds was evaluated by monitoring their cytotoxic effects against PC-3 cells by using MTT assay. We observed that compound 5f resulted in more than 50% cell death at 14 μM. Treatment of PC-3 cells with 5f provides apoptosis by flow cytometry. Western blotting showed decreased expression of pro-caspase 8 and 9. Our study shows that cancer cell treated with 5f has higher concentration of reactive oxygen species as compare to untreated sample, which facilitate cancerous cell to enter apoptosis. Exact mechanism by which ROS is generated after 5f treatment is still under study. Molecular docking study further strengthens the results obtained from in vitro experiments. Compound 5f can be considered as a promising leads for anticancer agent against prostate cancer cells due to its potent cytotoxic activity and apoptotic effect.
Shanghai Dynamic Industrial Co.,Ltd.
website:http://www.shdynamic.com
Contact:86-021 3392 6680
Address:Room 805 Information Tower, No.1403 Minsheng Road, Pudong New Area, Shanghai 200135, P. R. China
Guangzhou Congen Pharmatec Co.,Ltd.
website:https://www.congenpharma.com
Contact:86-020-82350801
Address:Room 501, Building G11, South China Advanced Materials Innovation Park, 31 Kefeng Road, Science City, Guangzhou, China 510663
Nantong LiKai Chemical Co.,Ltd
Contact:+86-513-89068669
Address:Jincheng Science Park
Contact:+86-22-26358246
Address:601-4-20, Fujiayuan, Tiantai Road, Hebei District, Tianjin, China
website:http://www.chemdow.com
Contact:0086-10-82435335
Address:Room 401,Unit 3,4th Floor,Shangdijiayuan,Shangdi East Road, Haidian District,Beijing
Doi:10.1039/c4cc03267e
(2014)Doi:10.1055/s-0033-1338578
(2014)Doi:10.1039/c4ob00629a
(2014)Doi:10.1134/S1070363214060334
()Doi:10.1021/ol050673s
(2005)Doi:10.1021/jo500007p
(2014)